These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18372384)

  • 1. Opioid withdrawal syndrome on switching from hydromorphone to alfentanil.
    McMunnigall F; Welsh J
    Palliat Med; 2008 Mar; 22(2):191-2. PubMed ID: 18372384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms of opioid withdrawal syndrome after switch from oxycodone to alfentanil.
    Carmichael JP; Lee MA
    J Pain Symptom Manage; 2010 Dec; 40(6):e4-6. PubMed ID: 20965693
    [No Abstract]   [Full Text] [Related]  

  • 4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal hydromorphone for intractable nonmalignant pain: a retrospective study.
    Du Pen S; Du Pen A; Hillyer J
    Pain Med; 2006; 7(1):10-5. PubMed ID: 16533191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The side effects of morphine and hydromorphone patient-controlled analgesia.
    Hong D; Flood P; Diaz G
    Anesth Analg; 2008 Oct; 107(4):1384-9. PubMed ID: 18806056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of an opioid taper algorithm in hematopoietic progenitor cell transplant recipients.
    Parran L; Pederson C
    Oncol Nurs Forum; 2002; 29(1):41-50. PubMed ID: 11817492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
    O'Connor AB; Zwemer FL; Hays DP; Feng C
    Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride.
    Katcher J; Walsh D
    J Pain Symptom Manage; 1999 Jan; 17(1):70-2. PubMed ID: 9919868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Opioid analgesics in the treatment of non-malignant chronic pain].
    Eriksen J; Clausen TG; Borgbjerg FM
    Ugeskr Laeger; 1994 Jan; 156(5):621-3, 626-7. PubMed ID: 7910424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial.
    Wirz S; Wartenberg HC; Elsen C; Wittmann M; Diederichs M; Nadstawek J
    Clin J Pain; 2006; 22(9):770-5. PubMed ID: 17057558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
    Zimmermann C; Seccareccia D; Booth CM; Cottrell W
    J Pain Palliat Care Pharmacother; 2005; 19(2):25-31. PubMed ID: 16061458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphine and hydromorphone-induced hyperalgesia in a hospice patient.
    Juba KM; Wahler RG; Daron SM
    J Palliat Med; 2013 Jul; 16(7):809-12. PubMed ID: 22925158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between withdrawal symptoms and medication pump residual volume in patients with implantable SynchroMed pumps.
    Taha J; Favre J; Janszen M; Galarza M; Taha A
    Neurosurgery; 2004 Aug; 55(2):390-3; discussion 393-4. PubMed ID: 15271246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices.
    Stearns L; Boortz-Marx R; Du Pen S; Friehs G; Gordon M; Halyard M; Herbst L; Kiser J
    J Support Oncol; 2005; 3(6):399-408. PubMed ID: 16350425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Opioid treatment of pain in angina pectoris].
    Hermann CK; Eriksen J
    Ugeskr Laeger; 2002 Apr; 164(17):2297-8. PubMed ID: 11989181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.
    Benítez-Rosario MA; Salinas-Martín A; Aguirre-Jaime A; Pérez-Méndez L; Feria M
    J Pain Symptom Manage; 2009 Jun; 37(6):1061-8. PubMed ID: 19171458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Delayed action and rapidly effective in combination. Hydromorphone--already a WHO stage 3 drug].
    MMW Fortschr Med; 2006 May; 148(19):47. PubMed ID: 16736708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.